Literature DB >> 26188826

The porcine valve type predicts obstructive thrombosis beyond the first three postoperative months in bioprostheses in the aortic position.

Nikolaus Jander1, Harriet Sommer2, Clarence Pingpoh3, Rolf-Peter Kienzle1, Gabriele Martin1, Wolfgang Zeh1, Gregor Pache4, Matthias Siepe3, Friedhelm Beyersdorf3, Martin Schumacher2, Franz-Josef Neumann1, Jan Minners5.   

Abstract

BACKGROUND: Obstructive thrombosis of bioprosthetic valves is considered rare but may have dramatic consequences for the individual patient including repeat valve replacement, thrombolysis, or long-term anticoagulation. Whether the risk of obstructive thrombosis is dependent on the type of bioprosthesis (porcine versus bovine pericardial) is uncertain. METHODS AND
RESULTS: Between 2007 and 2012 a total of 1751 patients received a single stented bioprosthesis in the aortic valve position, 749 (43%) were porcine and 1002 (57%) bovine. During a mean follow-up of 3.4±1.9years, obstructive thrombosis (identified by an increase in mean pressure gradient≥20mm Hg or a decrease in velocity ratio≥0.05 and confirmed by either ECG-gated computer tomography, a return to baseline of stenosis parameters under treatment with a vitamin K antagonist, or histology in case of reoperation) was diagnosed in 17 patients with a porcine (2.3%) and none with a bovine valve (p<0.001). The cumulative probability of developing an obstructive thrombosis was significantly higher in patients with a porcine valve (p<0.001 log-rank test). Adjusting for differences in baseline variables and stratification by the estimated propensity score showed that strata with a high probability of receiving a bovine valve had the highest number of obstructive thrombosis in porcine valves. These findings were further confirmed in a Poisson model and a competing risk model including all-cause mortality. Treatment of obstructive thrombosis with a vitamin K antagonist was safe and effective in 15/17 patients.
CONCLUSION: The porcine valve type is an independent predictor of obstructive thrombosis in bioprostheses in the aortic position.
Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Bioprosthesis; Obstructive thrombosis; Valvular heart disease

Mesh:

Year:  2015        PMID: 26188826     DOI: 10.1016/j.ijcard.2015.07.022

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  5 in total

1.  Course of early subclinical leaflet thrombosis after transcatheter aortic valve implantation with or without oral anticoagulation.

Authors:  Philipp Ruile; Nikolaus Jander; Philipp Blanke; Simon Schoechlin; Jochen Reinöhl; Michael Gick; Juergen Rothe; Mathias Langer; Jonathon Leipsic; Heinz-Joachim Buettner; Franz-Josef Neumann; Gregor Pache
Journal:  Clin Res Cardiol       Date:  2016-11-16       Impact factor: 5.460

Review 2.  Complementary role of cardiac CT in the assessment of aortic valve replacement dysfunction.

Authors:  Alastair J Moss; Marc R Dweck; John G Dreisbach; Michelle C Williams; Sze Mun Mak; Timothy Cartlidge; Edward D Nicol; Gareth J Morgan-Hughes
Journal:  Open Heart       Date:  2016-11-02

3.  Early cost-utility analysis of tissue-engineered heart valves compared to bioprostheses in the aortic position in elderly patients.

Authors:  Simone A Huygens; Isaac Corro Ramos; Carlijn V C Bouten; Jolanda Kluin; Shih Ting Chiu; Gary L Grunkemeier; Johanna J M Takkenberg; Maureen P M H Rutten-van Mölken
Journal:  Eur J Health Econ       Date:  2020-01-25

4.  Bioprosthetic Aortic Valve Thrombosis and Literature Review.

Authors:  Milan Radovanovic; Charles W Nordstrom; Richard D Hanna
Journal:  J Cardiovasc Dev Dis       Date:  2022-08-06

Review 5.  Clinical Valve Thrombosis and Subclinical Leaflet Thrombosis Following Transcatheter Aortic Valve Replacement: Is There a Need for a Patient-Tailored Antithrombotic Therapy?

Authors:  Liesbeth Rosseel; Ole De Backer; Lars Søndergaard
Journal:  Front Cardiovasc Med       Date:  2019-04-18
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.